Carrie Cox Net Worth

The estimated Net Worth of Carrie Smith Cox is at least $6.21 Million dollars as of 31 July 2023. Ms. Cox owns over 16,055 units of Cardinal Health stock worth over $5,877,878 and over the last 20 years she sold CAH stock worth over $0. In addition, she makes $328,521 as Independent Director at Cardinal Health.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Cox CAH stock SEC Form 4 insiders trading

Carrie has made over 35 trades of the Cardinal Health stock since 2004, according to the Form 4 filled with the SEC. Most recently she exercised 16,055 units of CAH stock worth $1,009,538 on 31 July 2023.

The largest trade she's ever made was buying 130,000 units of Cardinal Health stock on 13 June 2022 worth over $149,500. On average, Carrie trades about 3,520 units every 61 days since 2004. As of 31 July 2023 she still owns at least 51,856 units of Cardinal Health stock.

You can see the complete history of Ms. Cox stock trades at the bottom of the page.

Carrie Cox biography

Carrie S. Cox serves as Independent Director of the Company. Ms. Cox served as Chairman and Chief Executive Officer of Humacyte, Inc., a privately held, development stage company focused on regenerative medicine, from 2010 to 2018 and as its Executive Chairman from 2018 to 2019. She was Executive Vice President and President of Global Pharmaceuticals at Schering-Plough Corporation, a multinational branded pharmaceutical manufacturer, from 2003 until its merger with Merck & Co. in 2009. She was Executive Vice President and President of the Global Prescription Business of Pharmacia Corporation, a pharmaceutical and biotechnology company, from 1997 to 2003. Through her roles as an executive of Schering-Plough, President of Pharmacia’s Global Prescription business and Chief Executive Officer of Humacyte and as a licensed pharmacist, Ms. Cox brings to the Board substantial expertise in healthcare, particularly the branded pharmaceutical and international aspects. She draws on this experience in discussions relating to Pharmaceutical segment strategy, healthcare compliance and the opioid epidemic, including in meetings of the Board’s Ad Hoc Committee. Ms. Cox worked in the global branded pharmaceutical industry for over 30 years, giving her relevant experience with large, multinational healthcare companies in the areas of regulatory compliance, global markets and manufacturing operations. She also brings to the Board and to her role chairing our Human Resources and Compensation Committee, valuable perspectives and insights from her service on the boards of directors of Celgene, electroCore and Texas Instruments and prior service on the Array BioPharma board. She previously served as Chairman of the Board at Array BioPharma and Lead Director at Texas Instruments and currently sits on Texas Instruments’ Compensation Committee and Celgene’s Compensation and Development Committee

What is the salary of Carrie Cox?

As the Independent Director of Cardinal Health, the total compensation of Carrie Cox at Cardinal Health is $328,521. There are 12 executives at Cardinal Health getting paid more, with Michael Kaufmann having the highest compensation of $14,217,100.

How old is Carrie Cox?

Carrie Cox is 63, she's been the Independent Director of Cardinal Health since 2009. There are 7 older and 17 younger executives at Cardinal Health. The oldest executive at Cardinal Health, Inc. is John Losh, 74, who is the Independent Director.

What's Carrie Cox's mailing address?

Carrie's mailing address filed with the SEC is 12500, TI Boulevard, Lake Highlands, Bouchard, Dallas, Dallas County, Texas, 75243, United States.

Insiders trading at Cardinal Health

Over the last 23 years, insiders at Cardinal Health have traded over $135,712,519 worth of Cardinal Health stock and bought 2,709 units worth $199,571 . The most active insiders traders include Dean A Scarborough, George S Barrett, and Jeffrey William Henderson. On average, Cardinal Health executives and independent directors trade stock every 32 days with the average trade being worth of $5,146,997. The most recent stock trade was executed by Jessica L Mayer on 21 August 2024, trading 16,573 units of CAH stock currently worth $1,812,920.

What does Cardinal Health do?

cardinal health, inc. (nyse: cah), is a global integrated healthcare services and products company, providing customized solutions for hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. the company provides clinically-proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. cardinal health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. backed by nearly 100 years of experience, with more than 37,000 employees in nearly 60 countries, cardinal health ranks among the top 25 on the fortune 500. for more information, visit cardinalhealth.com, follow @cardinalhealth on twitter.

Complete history of Ms. Cox stock trades at Selecta Biosciences Inc, Texas Instruments, Cardinal Health, and ElectroCore Inc

Cardinal Health executives and stock owners

Cardinal Health executives and other stock owners filed with the SEC include:

• Michael Kaufmann,
  Chief Executive Officer, Director
• Victor Crawford,
  Chief Executive Officer - Pharmaceutical Segment
• Jason Hollar,
  Chief Financial Officer
• Stephen Mason,
  Chief Executive Officer - Medical Segment
• Jessica Mayer,
  Chief Legal and Compliance Officer
• Michael C. Kaufmann,
  CEO & Director
• David Evans,
  Independent Director
• Victor L. Crawford,
  Chief Exec. Officer of Pharmaceutical Segment
• Jason M. Hollar,
  Chief Financial Officer
• Stephen M. Mason,
  Chief Exec. Officer of Medical Segment
• Jessica L. Mayer,
  Chief Legal & Compliance Officer
• Gregory Kenny,
  Independent Non-Executive Chairman of the Board
• Carrie Cox,
  Independent Director
• John Losh,
  Independent Director
• Bruce Downey,
  Independent Director
• Dean Scarborough,
  Independent Director
• Patricia Hemingway Hall,
  Independent Director
• John Weiland,
  Independent Director
• Calvin Darden,
  Independent Director
• Nancy Killefer,
  Independent Director
• Akhil Johri,
  Independent Director
• Sheri Edison,
  Independent Director
• Brian Rice,
  Executive Vice President, Chief Information Officer and Customer Support Services
• Ola Snow,
  Chief Human Resource Officer
• Dr. Michele A. M. Holcomb Ph.D.,
  Exec. VP of Strategy & Corp. Devel. and Chief Strategy & Bus. Devel. Officer
• Brian S. Rice,
  Chief Information Officer, Exec. VP & Global Bus. Services
• Craig Cowman,
  Exec. VP of Global Sourcing
• Kevin Moran,
  VP of Investor Relations
• Patricia M. English,
  Sr. VP & Chief Accounting Officer
• Pamela O. Kimmet,
  Chief Human Resources Officer
• Michele Holcomb,
  EVP - Strategy & Corp. Dev.
• Falk T Stephen,
  EVP, Gen. Counsel & Corp. Sec.
• David P King,
  Director
• Craig S Morford,
  Chief Compliance Officer
• Colleen F. Arnold,
  Director
• Stuart G Laws,
  SVP & Chief Accounting Officer
• Donald M Jr. Casey,
  CEO, Medical Segment
• Clayton M Jones,
  Director
• David J Anderson,
  Director
• Patricia Morrison,
  Chief Information Officer
• Meghan Fitzgerald,
  EVP, Strategy & Health Policy
• Carole S Watkins,
  EVP - Human Resources
• Jon L Giacomin,
  CEO, Medical Segment
• George S Barrett,
  Chairman and CEO
• J Michael Losh,
  Director
• Deborah Weitzman,
  CEO, PSS Segment
• Jeffrey William Henderson,
  Executive Vice President
• David W Raisbeck,
  Director
• Michael A Lynch,
  CEO, Medical Segment
• Glenn Britt,
  Director
• Jean G Spaulding,
  Director
• John F Finn,
  Director
• Richard C Notebaert,
  Director
• Mark R Blake,
  EVP -- Strategy & Corp. Dev.
• James J Md Mongan,
  Director
• Jorge M Gomez,
  Chief Financial Officer
• Michael D Ohalleran,
  Director
• Vivek Jain,
  EVP - Corp Develop. & Strategy
• George H Conrades,
  Director
• Ivan K Fong,
  EVP, CLO & Secretary
• Robert D Walter,
  Chairman and CEO
• David L Schlotterbeck,
  Chmn & CEO-Clncl Techn & Svcs
• John B Mccoy,
  Director
• Philip L Francis,
  Director
• Matthew D Walter,
  Director
• R Kerry Clark,
  President and CEO
• Daniel J Walsh,
  EVP, Chf Ethcs & Compl Offcr
• Mark W Parrish,
  EVP; Group Pres.-Pharm. Distr.
• John F Havens,
  Director
• David Bing,
  Director
• Gary S Jensen,
  SVP - Corporate Controller
• Robert L Gerbig,
  Director
• Ronald K Labrum,
  CEO-Healthcare Supply Chn Svc
• Brendan A Ford,
  EVP - Corp. Development
• Anthony J Rucci,
  EVP & Chief Admin. Officer
• Joseph C Papa,
  Chmn & CEO, Pharm Techn & Svcs
• Stephen S Thomas,
  EVP-Group Pres.-AIS
• Gary D Dolch,
  EVP - Quality & Reg. Affairs
• George L Fotiades,
  President & COO
• Eric Slusser,
  SVP-Finance, CAO & Cntrllr
• Paul S Williams,
  EVP, CLO & Secretary
• Jody R Davids,
  EVP & CIO
• Richard J Miller,
  EVP & CFO
• Aaron E Alt,
  Chief Financial Officer
• Robert Azelby,
  Director
• Patricia M English,
  Chief Accounting Officer
• Christine Mundkur,
  Director
• Steven Barg,
  Director
• Michelle Brennan,
  Director
• Michelle D. Greene,
  Chief Information Officer
• Mary C. Scherer,
  Chief Accounting Officer